Medical scientists at the University of Leicester and Ferrara in Italy...Professor David Lambert who has been involved in the development ...He said: In a 2005 survey for the British Pain Society 975 people... Morphine produces its clinical effects by interaction with opioid... Clearly there is a place for new morphine like drugs without thes...
Medical scientists at the University of Leicester and Ferrara in Italy have developed a potential new pain-killing drug//. The composition of the drug and its benefits will be discussed at a public lecture on 20th March.
Professor David Lambert, who has been involved in the development the drug in collaboration with Dr Girolamo Calo in Ferrara Italy, believes the new drug – called UFP-101 - avoids many of the side effects of morphine, currently the ‘gold standard’ in pain reduction.
He said: "In a 2005 survey for the British Pain Society 975 people were questioned about pain. Twenty one percent experienced pain every day or most days equating to ~10million across the whole UK.
"Morphine produces its clinical effects by interaction with opioid receptors. In addition to acting as a pain killer this drug produces a number of unwanted side effects of importance from a clinical (e.g., depression of breathing, constipation and tolerance) and social (addiction) viewpoints.
"Clearly there is a place for new morphine like drugs without these side effects and the University of Leicester Anaesthesia Division has been at the forefront of such preclinical research."
Since appointment in 1991 as a lecturer Professor Lambert has been working on opioids and opioid receptors with particular emphasis on understanding receptor function and the design and evaluation of new drugs to target these receptors.
In collaboration with Dr Girolamo Calo his laboratory has characterised a prototype analgesic (pain killer), acting at a new opioid receptor, with a much reduced side effect profile.
In his inaugural lecture he will describe the current place of opioids in the clinic and development of UFP-101.
(Date:12/2/2008)...NGTON -- A new report from the Institute of Medici...ours and workloads to decrease the chances of fati...ning environment for these doctors in training. T...dents, work hours from the maximum average of 80 p...ate Medical Education (ACGME) in 2003, but rather ...
(Date:12/2/2008)... SAN DIEGO, Dec. 2 Stroller Stri...exercise program for new moms and their babies, ha...re for more than 40 years, has signed on as the co...ew partnership will strengthen the companies, shar.... , , "We are thrilled to have Pampers as o...
(Date:12/2/2008)... Comparator Study to Evaluate Efficacy of Commerci...WOODCLIFF LAKE, N.J., Dec. 2 Eisai... it plans to initiate the first clinical trial eva... injection) compared to Vidaza(R) (azacitidine) in...2 or high-risk myelodysplastic syndromes (MDS), a ...
(Date:12/2/2008)... Tenn., Dec. 2 Emdeon, a leading p...olutions for the healthcare industry,announced t...business,efficiency in healthcare. Emdeon unveile...ushealthcareindex.com ) to establish a national re... from a paper-based and phone-based,system to an ...
...pmental Biology, members of Dr. John Herr’s labora...eport the discovery// of a new protein within a sp...contraceptive drugs. “There’s considerable intere...es,” said Herr, who heads UVa’s Center for Researc...
...Medical Center have developed the first gene chip,...diagnosis of at// least five hereditary liver dise...causes of jaundice in children and adults, and pot...nt options. The Cincinnati Children's study resul...
...ad, medical science miracles will be a fact - tech...treatments will stand to// reshape the lives of pe...planning department at Eastern Virginia Medical Sc...sh Medical Journal based on these technologies. &...
...ck pain are effective, a new review of studies has...ological outcomes such as// depression and health-...’ experience of pain. “Because this analysis was...ative than previous reviews, we have the best evid...
(Date:11/25/2008)...ss Survival of Patients Receiving Litx versus Stan...ular Carcinoma , , BELLEVUE, Wash., Nov. 25...O) today announced the completion of enrollment in... Therapy(TM) (Litx(TM)) as a treatment for unresec...s hepatoma or primary liver cancer. , , The...
(Date:11/24/2008)...ewswire/ -- Takeda Pharmaceutical Company Limited ...earch & Development Center, Inc., U.S., announ... the U.S. Food and Drug Administration (FDA) recom...eatment of hyperuricemia in patients with gout. Th...ne panel member abstaining. The vote followed pres...
(Date:11/24/2008).../ -- Leaders of Schering-Plough Corporation (NYSE:... the company,s research pipeline, highlighting a r...entities in clinical trials or under regulatory re...search and development is adding strength and brea...mation," said Fred Hassan, chairman and CEO. "Our...
(Date:11/24/2008)... long-term commitment to hepatitis research , ...ll/ -- Schering-Plough Corporation (NYSE: SGP ) ...s lead investigational oral hepatitis C protease i...company believes boceprevir has the potential to b...bitor for treating chronic hepatitis C. The compa...
...Calif., June 05, 2007 /PRNewswire/ -- MAP,Pharmace... Phase 2,data from its MAP0004 migraine therapy cl...e Society Meeting at the Hyatt Regency,Chicago in ...was,accepted as a late-breaker, is entitled Rapid ...led Dihydroergotamine Mesylate,via a Novel Inhaler...
...une 05, 2007 /PRNewswire/ -- , Professor Home said...ppointing and,misleading in that they disregarded ...nt to patients and physicians. Most,significantly ...e,of any increase in cardiovascular death or death...T: Professor Philip Home, (44) 778-525-1736 , Ter...
...e BP monitor is designed to automatically measure ...BP along with heart rate. It's a Blood Pressure mo...ergometer and pharmacological stress test environm...ronments., ,Tango excels where other BP monit...
BD Visiswab Cotton Swab
...l, Philips Zymed 1810 Series offers retrospective ... the operator the flexibility to adjust the algori...application beyond the basic 1810 and you have eve...matic style that best meets the challenges of each...
...s STG for PC captures, displays, replays and analy...be effective in evaluating heart illnesses, pneumo...ase.,It provides objective evidence as a complem...time-expanded waveform displays, Phonocardiogra...